Apyx Medical Corporation
NASDAQ:APYXMedical - Devices
-$0.08 today
- Market cap
- $104.89M
- Beta
- 1.39
- P/E (TTM)
- -19.0
- EPS (TTM)
- -$0.22
Volume 0.19M
Average 0.18M
APYX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Apyx Medical CorporationNASDAQ: APYX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $2.11M (cash outflow) fell 49.2% year over year, ahead of the -55.1% change in trailing-twelve-month net income. Sequentially, it rose 73.1% from the prior quarter. Over 3 fiscal years it compounded at -21.9% a year.
Context
- Net income amounted to 21.0% of revenue in FY2025, down 28.0 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$8.49M (-23.5%) for the fiscal year ending Dec 2026, a step up from the -52.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.11M+73.1% QoQ
- Last fiscal yearDec 2025
- -$11.11M-52.9% YoY
- LTMMar 2026
- -$9.05M-55.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -49.2% | -2.1% | +47.1 pp |
| 1 year | -52.9% | -23.5% | +29.3 pp |
| 3-year CAGR | -21.9% | -31.4% | -9.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (11.11M) USD
- Year-over-year change
- +52.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.11M) | +52.9% |
| FY2024 | 2024-12-31 | (23.56M) | -25.0% |
| FY2023 | 2023-12-31 | (18.85M) | +19.0% |
| FY2022 | 2022-12-31 | (23.28M) | -53.1% |
| FY2021 | 2021-12-31 | (15.2M) | — |
Net Income vs competitors
How APYX compares with its peers on the latest reported figures
- APYX's LTM Mar 2026 net income of $9.05M is the 7th largest of the 8 companies compared; the peer median is $32.14M.
- Its year-over-year change of -55.1% is the lowest of 8, against a peer median of +14.1%.
- Net income amounts to 16.2% of revenue for APYX, versus a peer median of 104.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $26.68B | +43056.2% | +1.1% | 519699.0% | |
| LTM Mar 2026 | $50.14M | +11.8% | -8.1% | 145.8% | |
| LTM Mar 2026 | $45.34M | -20.5% | +22.1% | 62.7% | |
| LTM Mar 2026 | $32.14M | -2.6% | -10.3% | 56386.0% | |
| LTM Mar 2026 | $27.09M | +14.1% | +24.2% | — | |
| LTM Mar 2026 | $12M | +28.1% | +25.2% | 16.1% | |
| LTM Mar 2026 | $9.05M | -55.1% | -21.9% | 16.2% | |
| LTM Mar 2026 | $1.83M | +115.2% | — | 1.5% | |
| Peer median (excluding APYX) | $32.14M | +14.1% | +11.6% | 104.2% | |
Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (15.2M) | (23.28M) | (18.85M) | (23.56M) | (11.11M) |
| Depreciation & Amortization | 903K | 890K | 692K | 599K | 655K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.09M | 6.7M | 5.11M | 4.01M | 2M |
| Change in Working Capital | (1.84M) | (5.22M) | 5.54M | (1.25M) | (1.59M) |
| Accounts Receivables | (4.9M) | 1.92M | 3.97M | (2.04M) | (1.32M) |
| Inventory | (2.86M) | (5.57M) | 1.46M | 2.26M | (1.07M) |
| Accounts Payables | 1.15M | 67K | 25K | (63K) | 355K |
| Other Working Capital | 4.76M | (1.63M) | 88K | (1.41M) | 446K |
| Other Non-Cash Items | 603K | 628K | 2.25M | 2.15M | 2.04M |
| Operating Cash Flow | (10.45M) | (20.28M) | (5.25M) | (18.05M) | (8M) |
| Capital Expenditures | (723K) | (1.01M) | (533K) | (722K) | (1.11M) |
| Acquisitions (Net) | 195K | 0 | 7.41M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (195K) | 0 | (147K) | 0 | 0 |
| Investing Cash Flow | (723K) | (1.01M) | 6.73M | (722K) | (1.11M) |
| Debt Repayment | (238K) | (148K) | 35.04M | (20K) | (20K) |
| Common Stock Issued | 67K | 365K | 2.72M | 7M | 9.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 195K | 0 | (5.59M) | (235K) | 60K |
| Financing Cash Flow | 24K | 217K | 32.17M | 6.75M | 9.58M |
| Effect of Forex Changes | 103K | 395K | (191K) | 113K | (466K) |
| Net Change in Cash | (11.05M) | (20.68M) | 33.46M | (11.91M) | (1K) |
| Free Cash Flow | (11.17M) | (21.29M) | (5.78M) | (18.77M) | (9.12M) |
Apyx Medical Corporation
NASDAQ:APYX
Intrinsic Alpha fair value
Locked
Current Price
$2.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.